OHR Pharmaceutical Inc (OHRP)’s Positive OHR-102 Results Cause Waning Investor Sentiment To Spike

What does smart money think about OHR Pharmaceutical Inc?

Heading into the second quarter, a total of eight of the hedge funds tracked by Insider Monkey held long positions in this stock, a change of 33% from the close of the fourth quarter. With hedge funds’ capital changing hands, there exists an “upper tier” of key hedge fund managers who were boosting their stakes substantially.

Among the largest stockholders of OHR Pharmaceutical Inc at the end of the first quarter, Kevin Kotler’s Broadfin Capital was on top. The fund manager owned 1.78 million shares of the medical research company, with a market value of $4.50 million. Julian Baker & Felix Baker of Baker Bros. Advisors was the second largest investor of the company, owning 370,370 shares of the company valued at $941,000. Some of the other major investors of the company included Fred Knoll’s Knoll Capital Management, and Hal Mintz’s Sabby Capital.

Despite a slightly bearish outlook from hedge fund managers, we believe that positive medical results can turn the tide in favor of the company and we recommend a buy for the shares of OHR Pharmaceutical as a result.

Disclosure: None